In addition, a related compound, ladarixin, which has equivalent selectivity for CXCR1 and CXCR2 and is orally bioavailable, can delay diabetes onset in non-obese diabetic mice and is currently in a phase 2 clinical trial for new-onset diabetes type 1 (NCT02814838, ClinicalTrials.gov). This evidence concerns the gene CXCR2 and diabetes mellitus.